Investigational drug · Phase 3
Prevenar 13
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pneumococcal Infectious Diseases.
Phase 3Last checked: Nov 19, 2026Latest source record: May 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
294
Any phase or sponsor naming "Prevenar 13"
First trial start
2026
May 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Prevenar 13", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Infectious Diseases
Largest trials
Live from ClinicalTrials.gov: studies naming "Prevenar 13" as an intervention, largest first.
- Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.Status unknown
Sungkyunkwan UniversityAcademic, hospital or other
NCT04551248 · 1,000,000 participants (planned) · Start Aug 1, 2021 · Primary completion Mar 31, 2022
Drug: 10 or 13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine and 1 more · For: Pneumococcal Vaccine Adverse Reaction
Sites: Suwon, South Korea
PfizerPfizer (PFE)
NCT05794191 · 350,399 participants · Start Mar 22, 2023 · Primary completion Aug 15, 2024
Drug: Vaccine Administration · For: HIV; Pneumonia; Infections, Pneumococcal
Sites: New York, New York
- Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in AdultsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00744263 · 84,496 participants · Start Sep 2008 · Primary completion Oct 2013
Drug: VACCINE: placebo; VACCINE: 13-valent pneumococcal conjugate vaccine · For: Pneumonia, Pneumococcal; Pneumococcal Infections; 13-valent Pneumococcal Vaccine
Sites: Tilburg, Netherlands; Abbekerk, Netherlands; Alkmaar, Netherlands · 159 sites in all
- An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in ChildrenPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01439360 · 12,046 participants · Start Oct 1, 2011 · Primary completion Oct 31, 2014
Drug: Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A; Havrix Junior and 3 more · For: Influenza
Sites: Dhaka, Bangladesh; Antwerp, Belgium; Brussels, Belgium · 103 sites in all
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01702428 · 5,016 participants · Start Nov 9, 2012 · Primary completion Nov 25, 2014
Drug: Priorix; M-M-R II and 3 more · For: Rubella; Measles; Mumps
Sites: Dothan, Alabama; Phoenix, Arizona; Fayetteville, Arkansas · 90 sites in all
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsPivotal-lookingCompleted
Novartis VaccinesNovartis (NVS)
NCT00474526 · 4,545 participants · Start Mar 2007 · Primary completion Sep 2008
Drug: Meningococcal ACWY Conjugate Vaccine; DTaP-IPV-HBV and 6 more · For: Meningitis, Meningococcal
Sites: Bessemer, Alabama; Birmingham, Alabama; Downey, California · 63 sites in all
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01681992 · 4,538 participants · Start Oct 10, 2012 · Primary completion Feb 3, 2015
Drug: Priorix; M-M-R II and 3 more · For: Measles; Mumps; Rubella and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Jonesboro, Arkansas · 81 sites in all
- Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of ImmunizationCompleted
CHU de Quebec-Universite LavalAcademic, hospital or other
NCT02712177 · 4,535 participants · Start Aug 2008 · Primary completion Aug 2010
Drug: 4CMenb; diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB and 2 more · For: Meningococcal Infections
- Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00345683 · 4,021 participants · Start Jul 2007 · Primary completion Sep 2008
Drug: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014); PedvaxHIB and 3 more · For: Haemophilus Influenzae Type b; Neisseria Meningitidis
Sites: Birmingham, Alabama; Benton, Arkansas; Jonesboro, Arkansas · 57 sites in all
- Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01000974 · 4,003 participants · Start Jun 18, 2010 · Primary completion Nov 18, 2011
Drug: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108); ActHIB™ and 6 more · For: Haemophilus Influenzae Type b
Sites: Dothan, Alabama; Benton, Arkansas; Fayetteville, Arkansas · 63 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Immunogenicity of sequential conjugate and non-conjugate pneumococcal vaccination in dialysis patients and kidney transplant recipients: a 12-month serological follow-up.
Novelli S, Nun A, Cases A, et al. · Front Immunol 2026
- Pneumococcal meningitis among hospitalised children after introduction of pneumococcal conjugate vaccine in India: a sentinel hospital surveillance (2019-2022).
Chethrapilly Purushothaman GK, Rajkumar P, Kangusamy B, et al. · Lancet Reg Health Southeast Asia 2026
- Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in children under 5 years old in Zhejiang, China: A case-control study.
Liu Y, Lu ZJ, Yang JH, et al. · Int J Infect Dis 2026
- Evaluation of T-Cell Responses Following Sequential Vaccination with PCV13 and PPSV23 Against Streptococcus pneumoniae in Patients with Psoriasis.
Wojtakowski T, van de Sand L, Helmer L, et al. · Vaccines (Basel) 2025
- Immunogenicity and safety of a multi-human dose formulation of Biological E's 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6-8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study.
Thuluva S, Matur RV, Gunneri S, et al. · Front Immunol 2025
- Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis.
Garcia Quesada M, Peterson ME, Bennett JC, et al. · Lancet Infect Dis 2025
Also in development for Pneumococcal Infectious Diseases
- Sinovac PCV13Phase 32 trials
Sinovac Life Sciences Co., Ltd. · Pneumococcal Infectious Diseases, Pneumococcal Infectious Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.